Shattuck Labs, Inc.

STTK

Held by 2 specialist biotech funds

Share on X

Fund Holdings

OrbiMed Advisors Redmile Group

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 6,306,127Value: $23.0M

# Signal Note: OrbiMed Entry into Shattuck Labs OrbiMed's $23M inaugural position in STTK signals conviction in the company's proprietary Agonist Redirected Checkpoint (ARC) platform, which generates bispecific antibodies designed to enhance T-cell activation while reducing systemic toxicity. The investment likely reflects confidence in near-term catalysts including clinical data readouts for SL-172154 (TGF-β/PD-L1 bispecific in solid tumors, Phase 1b ongoing) and potentially SL-279252 (OX40/PD-L1 bispecific), which could validate the platform's ability to compete in the crowded I/O space. Given OrbiMed's track record in early-to-mid stage biotech bets, this suggests institutional-grade risk assessment of the science and management execution.

Redmile GroupNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

KRYS2 funds ADCT2 funds XENE2 funds COGT2 funds ORIC2 funds APLS1 fund RNA1 fund BIOA

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Redmile initiates $20.2M position in STTK** Redmile's entry into Shattuck Labs signals conviction in the company's dual-signaling platform for immuno-oncology, particularly ahead of clinical readouts for its lead program SL-172154 (Agonist/Antagonist) in solid tumors. The $20.2M stake (~5.5M shares) represents meaningful conviction from a healthcare-focused crossover investor, likely positioning for near-term data catalysts and potential partnership validation in a competitive cell therapy space.